CoChat

Gastrointestinal Safety Pharmacology in Drug Discovery and Development

Al-Saffar, Ahmad, da Costa, André Nogueira, Delaunois, Annie, Leishman, Derek J., Marks, Louise, Rosseels, Marie-Luce, Valentin, J.-P. · 2015 · Handbook of experimental pharmacology

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Abstract

Although the basic structure of the gastrointestinal tract (GIT) is similar across species, there are significant differences in the anatomy, physiology, and biochemistry between humans and laboratory animals, which should be taken into account when conducting a gastrointestinal (GI) assessment. Historically, the percentage of cases of drug attrition associated with GI-related adverse effects is small; however, this incidence has increased over the last few years. Drug-related GI effects are very diverse, usually functional in nature, and not limited to a single pharmacological class. The most common GI signs are nausea and vomiting, diarrhea, constipation, and gastric ulceration. Despite being generally not life-threatening, they can greatly affect patient compliance and quality of life. There is therefore a real need for improved and/or more extensive GI screening of candidate drugs in preclinical development, which may help to better predict clinical effects. Models to identify drug effects on GI function cover GI motility, nausea and emesis liability, secretory function (mainly gastric secretion), and absorption aspects. Both in vitro and in vivo assessments are described in this chapter. Drug-induced effects on GI function can be assessed in stand-alone safety pharmacology studies or as endpoints integrated into toxicology studies. In silico approaches are also being developed, such as the gut-on-a-chip model, but await further optimization and validation before routine use in drug development. GI injuries are still in their infancy with regard to biomarkers, probably due to their greater diversity. Nevertheless, several potential blood, stool, and breath biomarkers have been investigated. However, additional validation studies are necessary to assess the relevance of these biomarkers and their predictive value for GI injuries.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-3-662-46943-9_12

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 140 references

Research works printed but not linked: 4

  1. Anon (1995) Guidelines for general pharmacology studies—Japanese guidelines for non-clinical studies of drugs manual, pp. 71-80. Eds. Nippo Yakuji, Ltd
  2. Kerns E, Di L (eds) (2008) Drug-like properties: concepts, structure design and methods, 1st edn. Academic, London
  3. Redfern WS, Ewart L, Hammond TG, Bialecki R, Kinter L, Lindgren S, Pollard CE, Roberts R, Rolf M, Valentin J-P (2010) Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114(S1):1081
  4. Wood JG, Cheung LY (1996) Gastrointestinal secretion. In: Gregerson H, Lindkaer Jensen S, Moody F, Shokouh-Amari M (eds) Essentials of experimental surgery: gastroenterology (chapter 28). Harwood Academic, Amsterdam, pp 1–21

Cited by

See all 29

Metadata

Authors
Al-Saffar, A., da Costa, A. N., Delaunois, A., Leishman, D. J., Marks, L., Rosseels, M.-L., & Valentin, J.-P.
Affiliations
  • UCB Pharma (Belgium) (BE)
  • Eli Lilly (United States) (US)
  • AstraZeneca (United Kingdom) (GB)
Corresponding author
Valentin, J.-P.
Venue
Handbook of experimental pharmacology
Published
2015
Volume
229
Pages
291-321
ISSN
  • 0171-2004 (ISSN-L)
  • 1865-0325
OpenAlex
W1923919220
Cited by
29
References
139
Citations by year
2026: 2 · 2025: 3 · 2024: 1 · 2023: 5 · 2022: 2 · 2020: 2 · 2019: 6 · 2018: 5 · 2017: 1 · 2016: 2
FWCI
14.13
Type
book chapter
Language
en
Open access
closed
Licence
Locations
  • Handbook of experimental pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords
drug-induced gastrointestinal injury, drug attrition, nausea and vomiting, diarrhea, constipation, gastric ulcer, gastrointestinal motility, gastric secretion, drug absorption, preclinical drug screening, in vitro and in vivo models, gut-on-a-chip
MeSH terms
Animals, Drug and Narcotic Control, Drug Evaluation, Preclinical, Gastric Emptying, Gastrointestinal Motility, Humans, Intestinal Absorption, Biomarkers, Gastrointestinal Tract, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gastrointestinal Safety Pharmacology in Drug Discovery and Development. https://app.cochat.ai/papers/10.1007/978-3-662-46943-9_12
The paper
Al-Saffar, A., da Costa, A. N., Delaunois, A., Leishman, D. J., Marks, L., Rosseels, M.-L., & Valentin, J.-P. (2015). Gastrointestinal Safety Pharmacology in Drug Discovery and Development. Handbook of experimental pharmacology. https://doi.org/10.1007/978-3-662-46943-9_12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.